A person who has experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case: 

1. Face-to-face contact with a probable or confirmed case within 1 meter and for at least 15 minutes
2. Direct physical contact with a probable or confirmed case
3. Direct care for a patient with probable or confirmed COVID-19 disease without the use of recommended personal protective equipment

OR

1. Other situations as indicated by local risk assessments

WHO

Suspected case of SARS-CoV-2 infection (three options, A through C):

A. A person who meets the clinical AND epidemiological criteria:

Clinical criteria:

1. Acute onset of fever AND cough;

OR

1. Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general weakness/fatigue,1 headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status.

AND

Epidemiological criteria:  

1. Residing or working in a setting with high risk of transmission of the virus: for example, closed residential settings and humanitarian settings, such as camp and camp like settings for displaced persons, any time within the 14 days before symptom onset;

OR

1. Residing in or travel to an area with community transmission anytime within the 14 days before symptom onset;

OR

1. Working in health setting, including within health facilities and within households, anytime within the 14 days before symptom onset.

B. A patient with severe acute respiratory illness (SARI: acute respiratory infection with history of fever or measured fever of ≥ 38 C°; and cough; with onset within the last 10 days; and who requires hospitalization).

C. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2 antigen-detecting rapid diagnostic test (Ag-RDT).

CDC

One or more of the following exposures in the 14 days before onset of symptoms:

1. Close contact** with a confirmed or probable case of COVID-19 disease; OR
2. Close contact** with a person with:
   • clinically compatible illness AND
   • linkage to a confirmed case of COVID-19 disease.
3. Travel to or residence in an area with sustained, ongoing community transmission of SARS-CoV-2.
4. Member of a risk cohort as defined by public health authorities during an outbreak.

**Close contact is defined as being within 6 feet for at least a period of 10 minutes to 30 minutes or more depending upon the exposure. In healthcare settings, this may be defined as exposures of greater than a few minutes or more. Data are insufficient to precisely define the duration of exposure that constitutes prolonged exposure and thus a close contact.

WHO

A person who has experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case: 

1. Face-to-face contact with a probable or confirmed case within 1 meter and for at least 15 minutes
2. Direct physical contact with a probable or confirmed case
3. Direct care for a patient with probable or confirmed COVID-19 disease without the use of recommended personal protective equipment

OR

1. Other situations as indicated by local risk assessments

CDC

Clinical Criteria

At least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s)

OR

At least one of the following symptoms: cough, shortness of breath, or difficulty breathing

OR

Severe respiratory illness with at least one of the following:

• Clinical or radiographic evidence of pneumonia, OR
• Acute respiratory distress syndrome (ARDS).

AND

No alternative more likely diagnosis

Laboratory Criteria

Laboratory evidence using a method approved or authorized by the U.S. Food and Drug Administration (FDA) or designated authority:

Confirmatory laboratory evidence:

• Detection of severe acute respiratory syndrome coronavirus 2 ribonucleic acid (SARS-CoV-2 RNA) in a clinical specimen using a molecular amplification detection test

Presumptive laboratory evidence:

• Detection of specific antigen in a clinical specimen
• Detection of specific antibody in serum, plasma, or whole blood indicative of a new or recent infection*

*Serologic methods for diagnosis are currently being defined.

WHO

Confirmed case of SARS-CoV-2 infection (three options, A through C):

1. A person with a positive Nucleic Acid Amplification Test (NAAT)
2. A person with a positive SARS-CoV-2 Ag-RDT AND meeting either the probable case definition or suspected criteria A OR B
3. An asymptomatic person with a positive SARS-CoV-2 Ag-RDT AND who is a contact of a probable or confirmed case.